サポートされていないブラウザを使用しています。
当サイトの一部の機能が正しく機能しない場合があります。最適なユーザーエクスペリエンスのため、このサイトはChrome、Firefox、Safari、またはEdgeでご覧ください。

学会及びパブリケーション

学会資料

以下の学会で発表された英語の抄録、ポスター、プレゼンテーションにアクセス

2024年2月

European Society for Medical Oncology Virtual Plenary (ESMO)

2024年1月

Congrès de Pneumologie de Langue Française (CPLF)

2024年1月

Biennale Monégasque de Cancérologie (BMC)

2024年1月

米国臨床腫瘍学会 - 消化器癌シンポジウム(ASCO-GI)

米国臨床腫瘍学会 - 消化器癌シンポジウム(ASCO-GI)

2024年1月(米国カリフォルニア州サンフランシスコ)
2023年12月

米国血液学会(ASH)

米国血液学会(ASH)

2023年12月(米国カリフォルニア州サンディエゴ)

ポスター

Acquired mutations in patients with relapsed/refractory chronic lymphocytic leukemia who progressed in the ALPINE study Broad superiority of zanubrutinib over bendamustine + rituximab across multiple high-risk factors: biomarker subgroup analysis in the phase 3 SEQUOIA study in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma without del(17p) Clinical outcomes in patients with Waldenström macroglobulinemia (WM) receiving ibrutinib on the phase 3 ASPEN study ≥1 year after transitioning to zanubrutinib First results from a phase 1, first-in-human study of Bruton's tyrosine kinase (BTK) degrader BGB-16673 in patients (pts) with relapsed or refractory (R/R) B-cell malignancies Health-related quality of life (HRQoL) in patients with relapsed/refractory follicular lymphoma (R/R FL) treated with zanubrutinib+ obinutuzumab versus obinutuzumab monotherapy: the ROSEWOOD trial Impact of real-world treatment sequencing patterns on time to next treatment among patients with chronic lymphocytic leukemia in the United States Monotherapy with second-generation BCL2 inhibitor sonrotoclax (BGB-11417) is well tolerated with high response rates in patients with relapsed/refractory marginal zone lymphoma: data from an ongoing phase 1 study Number needed to treat analyses of zanubrutinib in relapsed/refractory chronic lymphocytic leukemia Real-world Bruton tyrosine kinase inhibitor (BTKi) treatment patterns among patients with chronic or small lymphocytic leukemia (CLL/SLL) in US community oncology practices Real-world evaluation of treatment discontinuation and healthcare resource utilization in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma Real-world patterns of care and financial burden of patients with follicular lymphoma in the United States Real-world switching pattern, persistence, and associated healthcare resource utilization of Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma in the United States Recent patterns of care with BTK inhibitors and distribution of social determinants of health among patients with CLL/SLL in the US community setting Similar efficacy of ibrutinib arms across ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: a matching-adjusted indirect comparison Tislelizumab, an anti-PD1 antibody, in patients with relapsed/refractory classical Hodgkin lymphoma in TIRHOL BGB-A317-210: a prospective multicenter Lysa phase 2 study conducted in Western countries Toxicity, progression-free survival, and quality of life of patients treated with zanubrutinib versus ibrutinib: a Q-TWiST analysis from the ALPINE study in relapsed or refractory chronic lymphocytic leukemia Zanubrutinib in acalabrutinib-intolerant patients (pts) with B-cell malignancies

抄録

A phase 4, observational study evaluating the efficacy and safety of the Bruton tyrosine kinase inhibitor (BTKi) zanubrutinib in patients with Waldenström macroglobulinemia (WM) Acquired mutations in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) that progressed in the ALPINE study Broad superiority of zanubrutinib (zanu) over bendamustine + rituximab (BR) across multiple high-risk factors: Biomarker subgroup analysis in the phase 3 SEQUOIA study in patients with treatment-naive (TN) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) without del(17p) Clinical outcomes in patients with Waldenström macroglobulinemia (WM) receiving ibrutinib on the phase 3 ASPEN study ≥1 year after transitioning to zanubrutinib Combination treatment with sonrotoclax (BGB-11417), a second-generation BCL2 inhibitor, and zanubrutinib, a Bruton tyrosine kinase (BTK) inhibitor, is well tolerated and achieves deep responses in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (TN-CLL/SLL): data from an ongoing phase 1/2 study Extended follow-up of ALPINE randomized phase 3 study confirms sustained superior progression-free survival of zanubrutinib versus ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL) First results from a phase 1, first-in-human study of Bruton's tyrosine kinase (BTK) degrader BGB-16673 in patients (pts) with relapsed or refractory (R/R) B-cell malignancies Genomic landscape of ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies treated with zanubrutinib in a phase 2 study Health-related quality of life (HRQoL) in patients with relapsed/refractory follicular lymphoma (R/R FL) treated with zanubrutinib+ obinutuzumab versus obinutuzumab monotherapy: the ROSEWOOD trial Impact of real-world treatment sequencing patterns on time to next treatment among patients with chronic lymphocytic leukemia in the United States Monotherapy with second-generation BCL2 inhibitor sonrotoclax (BGB-11417) is well tolerated with high response rates in patients with relapsed/refractory marginal zone lymphoma: data from an ongoing phase 1 study Number needed to treat analyses of zanubrutinib in relapsed/refractory chronic lymphocytic leukemia Real-world Bruton tyrosine kinase inhibitor (BTKi) treatment patterns among patients with chronic or small lymphocytic leukemia (CLL/SLL) in US community oncology practices Real-world evaluation of treatment discontinuation and healthcare resource utilization in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma Real-world patterns of care and financial burden of patients with follicular lymphoma in the United States Real-world switching pattern, persistence, and associated healthcare resource utilization of Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma in the United States Recent patterns of care with BTK inhibitors and distribution of social determinants of health among patients with CLL/SLL in the US community setting Similar efficacy of ibrutinib arms across ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: a matching-adjusted indirect comparison Sonrotoclax (BGB-11417) in combination with dexamethasone for the treatment of relapsed/refractory multiple myeloma with t(11;14): safety, efficacy, and determination of recommended phase 2 dose Tislelizumab, an anti-PD1 antibody, in patients with relapsed/refractory classical Hodgkin lymphoma in TIRHOL BGB-A317-210: a prospective multicenter Lysa phase 2 study conducted in Western countries Toxicity, progression-free survival, and quality of life of patients treated with zanubrutinib versus ibrutinib: a Q-TWiST analysis from the ALPINE study in relapsed or refractory chronic lymphocytic leukemia Zanubrutinib in acalabrutinib-intolerant patients (pts) with B-cell malignancies Zanubrutinib vs FCR in fit treatment-naive patients with chronic lymphocytic leukemia: a matching-adjusted indirect comparison
2023年12月

欧州臨床腫瘍学会-がん免疫(ESMO-IO)


最新のパブリケーション

青と赤の分子のバナー画像 あなたやあなたの所属機関が購読している学術誌によっては、入手できない論文もあります。

パブリケーション・学会資料の検索

このウェブサイトは、世界中の医学学会から刊行されたパブリケーションや学会資料のデータベースを収録しています。下の検索エンジンを使用して、ニーズに見合った情報にアクセスいただけます。

BeiGene, Ltd.は、ユーザーが個人的に情報収集、学習、通信する目的で当サイトを運営しています。サイトの閲覧は自由です。ただし、BeiGeneの書面による許可なく、テキストや画像を含め、当サイトのコンテンツを配布、変更、送信、再利用、再投稿したり、公的な目的または商業目的で使用することを禁じます。  
 
これは、科学的情報および臨床情報のためのオンライン医療リソースです。BeiGeneは、当サイトの情報がすべての国や地域に適切であることを表明するものではありません。当サイトにアクセスするユーザーは、適用される現地の法律を遵守する責任を負います。 

一部のコンテンツは英語のみとなっています。

Powered by Translations.com GlobalLink OneLink Software